Central retinal vein occlusion (CRVO) is a rare side effect of MEK inhibitors. • MEK inhibitor-associated CRVO may result in permanent drug discontinuation.
Novel Insights• MEK inhibitor-associated CRVO may be associated with hyperhomocysteinemia, suggesting a potential role for hyperhomocysteinemia screening prior to initiation of MEK inhibitor therapy. • In this small cohort, MEK inhibitor-associated CRVO was associated with good visual recovery following intravitreous anti-VEGF.
AbstractBackground: Central retinal vein occlusion (CRVO) is a visually threatening event that has rarely been observed in patients taking MEK1/2 inhibitors and that may necessitate permanent discontinuation of a potentially efficacious therapy. We investigated the clinical characteristics of CRVO in patients on mitogen-activated protein kinase kinase (MEK) inhibition to better understand their predisposing factors and clinical course. Case Series: This was a single-center, ret-inhibitor-associated CRVO is a rare event which can exhibit visual recovery after drug cessation and intravitreous anti-VEGF injections. In this cohort, it was associated with hyperhomocysteinemia and genetic mutations in MTHFR, suggesting a potential role for hyperhomocysteinemia screening prior to initiation of MEK inhibitor therapy.